Biovica DiviTum (R) TKa results published in the Journal of Medical Economics

0


UPPSALA, SWEDEN / ACCESSWIRE / November 16, 2021 / Biovica International (STO: BIOVIC-B) (STO: BIOVIC.B) (FRA: 9II)

Biovica, active in cancer diagnostics, today announced that the results of a DiviTum®TKa budget impact model have been published in the Journal of Medical Economics. This publication expands on the data presented at the ISPOR 2021 meeting. The results of the model show that monitoring with DiviTum®TKa can save up to three times the additional expenses compared to the current management of patients with a metastatic breast cancer.

Caring for patients with metastatic breast cancer is a significant burden on healthcare systems due to the cost of therapies, the cost of surveillance tests and the management of side effects. The results of this study show that adding DiviTumTKa to care could result in a net cost reduction of up to three times the expense of the new test. The savings come from reducing the use of other monitoring tools such as CT scans and bone scans, and from shortening the length of time a patient receives expensive medical treatments that ultimately prove ineffective.

“Our analysis showed that the inclusion of DiviTum®TKa could reduce the use of a substantial proportion of traditional surveillance. If the use of DiviTum®TKa can also predict the lack of benefit from expensive CDK4 / 6i therapy and clinicians then act on this information in a timely manner, our model suggests that this will result in substantial savings for patients. and health plans, ”said Scott D. Ramsey of the Fred Hutchison Cancer Research Center.

“This analysis reinforces our belief that DiviTum®TKa will improve patients’ lives and reduce healthcare costs. From discussions with patients, we also know that they prefer a regular blood test as a better option than current monitoring practices. said Anders Rylander, CEO of Biovica.

The study publication is included in the November 2021 issue of the Journal of Medical Economics https://doi.org/10.1080/13696998.2021.2003674

Contact

Anders Rylander, CEO
Phone: + 46-18-444 48 35
Email: anders.rylander@biovica.com

Biovica – Treatment decisions with confidence

Biovica develops and markets blood biomarker tests to evaluate the effectiveness of cancer treatments. Biovica’s DiviTum® assay measures cell proliferation by detecting a biomarker in the bloodstream. The test has successfully demonstrated its ability to assess therapy efficacy early in several clinical trials. The first application of DiviTum is the monitoring of the treatment of patients with metastatic breast cancer. Biovica’s vision is that all cancer patients will receive optimal treatment from day one. Biovica collaborates with world renowned cancer institutes and pharmaceutical companies. DiviTum is CE marked and registered with the Swedish Medicines Agency. Biovica shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the authorized advisor of the company, info@fnca.se, +46 8 528 00 399. For more information, please visit: www.biovica.com.

Attachments

Biovica’s DiviTum®TKa results published in the Journal of Medical Economics

THE SOURCE: Biovica International

See the source version on accesswire.com:
https://www.accesswire.com/673068/Biovicas-DiviTumRTKa-Results-Published-in-Journal-of-Medical-Economics


Share.

About Author

Comments are closed.